Employees: 1,462
Size Jinghua Pharmaceutical (002349.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $785M, the 2628th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.64 on 18 Nov 2026.
Performance Over six months the shares fell 7.7%, against -4.7% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 19 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median +7.3%); the operating margin is 19.9% (peer median 8.9%).
Valuation It trades at 3.1× enterprise value to sales against a peer median of 2.5× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.7 points above its cost of capital (5.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.48B | CN¥1.45B | CN¥1.39B | CN¥1.50B | CN¥1.56B |
| Revenue growth | — | +4% | -7% | -4% | — |
| Gross profit | CN¥814M | CN¥726M | CN¥665M | CN¥702M | CN¥681M |
| EBITDA | n/a | CN¥347M | CN¥300M | CN¥372M | CN¥323M |
| Net income | CN¥233M | CN¥219M | CN¥213M | CN¥248M | CN¥212M |
| Free cash flow | CN¥270M | CN¥326M | CN¥290M | CN¥270M | CN¥305M |
| Capital expenditure | CN¥30.4M | CN¥20.3M | CN¥30.9M | CN¥28.4M | CN¥61.6M |
| Total debt | CN¥13.9M | CN¥77.3M | CN¥35.0M | CN¥36.0M | CN¥39.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002349.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.1% | -0.9% | 5th lowest of 19 |
| 6-month return | -7.7% | -4.7% | 8th lowest of 19 |
| Distance from 52-week high | -30.8% | -32.8% | 8th highest of 19 |
| Revenue growth (TTM) | +1.9% | +7.3% | 7th lowest of 19 |
| Operating margin | 19.9% | 8.9% | 4th highest of 19 |
| EV / Sales | 3.1× | 2.5× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | -2.5% | 6.6% | 3rd least demanding of 12 |
| Growth delivered (Del g) | +2.6% | +10.1% | 6th lowest of 12 |
| Hurdle (Req g minus delivered) | -5.1 pp | -3.1 pp | 6th least demanding of 12 |
| ROIC minus cost of capital | +4.7 pp | -0.0 pp | 6th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | 789.4× | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 1.8× | 4.6% | +22.5% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |